DE69911240D1 - Zusammensetzungen, enthaltend mikronisiertes eplerenon - Google Patents

Zusammensetzungen, enthaltend mikronisiertes eplerenon

Info

Publication number
DE69911240D1
DE69911240D1 DE69911240T DE69911240T DE69911240D1 DE 69911240 D1 DE69911240 D1 DE 69911240D1 DE 69911240 T DE69911240 T DE 69911240T DE 69911240 T DE69911240 T DE 69911240T DE 69911240 D1 DE69911240 D1 DE 69911240D1
Authority
DE
Germany
Prior art keywords
compositions containing
containing micronized
micronized eplerenone
eplerenone
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69911240T
Other languages
English (en)
Other versions
DE69911240T2 (de
Inventor
S Thosar
D Gokhale
S Tolbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22339668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69911240(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of DE69911240D1 publication Critical patent/DE69911240D1/de
Application granted granted Critical
Publication of DE69911240T2 publication Critical patent/DE69911240T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE69911240T 1998-12-09 1999-12-08 Zusammensetzungen, enthaltend mikronisiertes eplerenon Expired - Lifetime DE69911240T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11164698P 1998-12-09 1998-12-09
US111646P 1998-12-09
PCT/US1999/029136 WO2000033847A1 (en) 1998-12-09 1999-12-08 Micronized eplerenone compositions

Publications (2)

Publication Number Publication Date
DE69911240D1 true DE69911240D1 (de) 2003-10-16
DE69911240T2 DE69911240T2 (de) 2004-07-15

Family

ID=22339668

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69911240T Expired - Lifetime DE69911240T2 (de) 1998-12-09 1999-12-08 Zusammensetzungen, enthaltend mikronisiertes eplerenon

Country Status (30)

Country Link
US (7) US6410054B1 (de)
EP (1) EP1135139B1 (de)
JP (1) JP2002531508A (de)
KR (1) KR100671275B1 (de)
CN (1) CN1230179C (de)
AR (1) AR028982A1 (de)
AT (1) ATE249223T1 (de)
AU (1) AU763166B2 (de)
BR (1) BR9915964A (de)
CA (1) CA2326842A1 (de)
CZ (1) CZ20011942A3 (de)
DE (1) DE69911240T2 (de)
DK (1) DK1135139T3 (de)
EA (1) EA003266B1 (de)
ES (1) ES2207977T3 (de)
HK (1) HK1041641B (de)
HU (1) HU224428B1 (de)
ID (1) ID30115A (de)
IL (1) IL143301A0 (de)
IS (1) IS2325B (de)
MY (1) MY125651A (de)
NO (1) NO20012782L (de)
NZ (1) NZ511869A (de)
PL (1) PL198425B1 (de)
PT (1) PT1135139E (de)
TR (1) TR200101643T2 (de)
TW (1) TWI234459B (de)
UA (1) UA74141C2 (de)
WO (1) WO2000033847A1 (de)
ZA (1) ZA200104361B (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
PT1175220E (pt) * 1999-12-08 2005-07-29 Pharmacia Corp Composicoes de eplerenona em nanoparticulas
EP1527782A1 (de) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanopartikelzusammensetzungen enthaltend Eplerenon
WO2001087284A2 (en) * 2000-05-11 2001-11-22 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
EP1368009A2 (de) * 2000-07-27 2003-12-10 Pharmacia Corporation Aldosteron-blocker zur behandlung oder vorbeugung von entzündungsverwandten störungen
US20040235809A1 (en) * 2000-07-27 2004-11-25 Alexander John C Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure
WO2002017895A2 (en) * 2000-08-28 2002-03-07 Pharmacia Corporation Use of an aldosterone receptor antagonist to improve cognitive function
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AU2002308295B2 (en) 2001-03-12 2007-08-23 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
US6962715B2 (en) * 2001-10-24 2005-11-08 Hewlett-Packard Development Company, L.P. Method and dosage form for dispensing a bioactive substance
US20040173147A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
US20040173146A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
GEP20063811B (en) * 2001-07-19 2006-05-10 Pharmacia Corp Combination of Aldosterone Receptor Antagonist and HMG COA Reductase Inhibitor
MXPA04005803A (es) * 2001-12-13 2004-11-01 Pharmacia Corp Metodos para tratamiento o profilaxis de efectos patogenicos mediados por aldosterona en un sujeto utilizando un antagonista de aldosterona epoxi-esteroidal.
CA2473797A1 (en) * 2002-01-30 2003-08-07 Pharmacia Corporation Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
MXPA04008307A (es) * 2002-02-26 2004-11-26 Astrazeneca Ab Formulacion farmaceutica de iressa que comprende un derivado de celulosa soluble en agua.
JP2005520856A (ja) * 2002-03-20 2005-07-14 ファルマシア コーポレーション 貯蔵時に安定なエプレレノン製剤
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
EP1982719A1 (de) * 2002-04-26 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Behandlung von Bluthochdruck bei Frauen mit einer Hormonersatztherapie
US20040048840A1 (en) * 2002-08-23 2004-03-11 Pharmacia Corporation Modulation of matrix metalloproteinase (MMP) activity with aldosterone blocker(s)
CA2500065A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
AU2002368326A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
DK1558265T3 (da) * 2002-11-05 2010-03-15 Bayer Schering Pharma Ag Anvendelse af dropspirenon til behandling af hypertension
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
AU2002356294A1 (en) * 2002-12-13 2004-07-09 Jagotec Ag A topical nanoparticulate spironolactone formulation
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
NZ543109A (en) * 2003-04-25 2008-06-30 Novacardia Inc Method of improved diuresis in individuals with impaired renal function
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
KR100473422B1 (ko) * 2003-06-12 2005-03-14 박원봉 렉틴 함유 천연물의 장용성 코팅용 조성물
AU2004249211A1 (en) * 2003-06-16 2004-12-29 Andrx Pharmaceuticals, Llc Oral extended-release composition
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
US20050031683A1 (en) * 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US7282217B1 (en) * 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
ES2734057T3 (es) * 2003-09-12 2019-12-04 Amgen Inc Formulación de disolución rápida que comprende cinacalcet HCl
CA2533887A1 (en) * 2003-09-30 2005-04-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
US20050203482A1 (en) * 2004-03-15 2005-09-15 Chinea Vanessa I. Pharmaceutical dispensing apparatus and method
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN101094671A (zh) * 2004-04-16 2007-12-26 美国诺华卡迪亚公司 包含腺苷a1受体拮抗剂和醛固酮抑制剂的组合疗法
US8075910B2 (en) 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
US7846466B2 (en) * 2004-06-10 2010-12-07 Northwestern University Biodegradable scaffolds and uses thereof
US20060134212A1 (en) * 2004-09-02 2006-06-22 Forest Laboratories, Inc. Lercanidipine immediate release compositions
US20060165788A1 (en) * 2004-09-09 2006-07-27 Wattanaporn Abramowitz Lercanidipine pH dependent pulsatile release compositions
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
AU2005307994B2 (en) * 2004-11-23 2009-07-23 Dong Wha Pharm. Co., Ltd An oral preparation having improved bioavailability
WO2006097342A1 (en) * 2005-03-17 2006-09-21 Synthon B.V. Process for making steroidal compounds
US20060252738A1 (en) * 2005-05-06 2006-11-09 Phero Tech Inc. Method for preparing and using water-based steroid pheromone compositions
US20060275356A1 (en) * 2005-05-25 2006-12-07 Burgess James W Pharmaceutical compositions for treating or preventing coronary artery disease
WO2007012960A1 (en) * 2005-07-29 2007-02-01 Glenmark Pharmaceuticals Limited Pharmaceutical compositions of eplerenone
US20070095705A1 (en) * 2005-10-31 2007-05-03 Legault Dennis X Array of packages
CN101375157B (zh) * 2006-01-13 2015-06-17 印第安纳大学研究和科技公司 用于治疗涉及对肺中存在的结缔组织自身免疫反应的肺病的分子
US20070184163A1 (en) * 2006-02-07 2007-08-09 International Flavors, & Fragrances Inc. Non-hygroscopic flavor particles
WO2007102169A1 (en) * 2006-03-08 2007-09-13 Jubilant Organosys Limited Extended release pharmaceutical formulation of venlafaxine and method of manufacturing the same
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
ES2351947T3 (es) * 2006-05-31 2011-02-14 Vertex Pharmaceuticals Incorporated Formulaciones orales de liberacion controlada de un inhibidor de la enzima convertidora de interleucina-1-beta.
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
DE102006033723A1 (de) * 2006-07-21 2008-01-24 Bayer Technology Services Gmbh Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
EP2124959A4 (de) * 2006-12-21 2011-09-14 Alphapharm Pty Ltd Pharmazeutische zusammensetzung
CA2675538C (en) * 2007-01-22 2017-02-28 Genpharm Ulc Oral pharmaceutical compositions comprising unmicronized nebivolol or a nebivolol analogue as active ingredient, and a decreased ratio of wetting agent to active ingredient
AR065096A1 (es) * 2007-02-01 2009-05-13 Takeda Pharmaceutical Preparacion solida
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
US20090232896A1 (en) * 2008-03-11 2009-09-17 Mallinckrodt Inc. Use of Magnesium Stearate Dihydrate for Lubrication of Solid Pharmaceutical Compositions
BRPI0917206B1 (pt) * 2008-07-31 2018-04-17 Clarke Mosquito Control Products, Inc. Método para a formação de uma pastilha comprimida de liberação dupla, pastilhas comprimidas e método para a fabricação de uma matriz sólida de liberação prolongada
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions
US8545892B2 (en) 2009-06-26 2013-10-01 Nano Pharmaceutical Laboratories, Llc Sustained release beads and suspensions including the same for sustained delivery of active ingredients
DK2470165T3 (en) * 2009-08-28 2018-06-06 Hercules Llc FILM COATING COMPOSITION OF SOLID POWDER COMPOUNDS
US9345848B2 (en) 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
ES2550033T3 (es) 2009-12-23 2015-11-04 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor
US20120308652A1 (en) * 2009-12-23 2012-12-06 Daniela Stumm Oral form of administration comprising entecavir
JP5669837B2 (ja) * 2010-06-16 2015-02-18 帝人ファーマ株式会社 放出制御型の有核錠剤
TR201007653A2 (tr) * 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
KR20120093461A (ko) * 2011-01-27 2012-08-23 양지화학 주식회사 정제형 감미료 조성물 및 그 제조방법
JP6284884B2 (ja) 2011-11-25 2018-02-28 ビルギチ，マフムト 吸入装置
EP2875359A4 (de) 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science Zusammensetzungen und verfahren zur behandlung oder prävention von stoffwechselsyndromerkrankungen
CN110354132A (zh) 2012-06-04 2019-10-22 药品循环有限责任公司 布鲁顿酪氨酸激酶抑制剂的晶形
FR3001890B1 (fr) * 2013-02-08 2015-08-07 Greenpharma Sas Composition dermatologique pour repousse des poils ou des cheveux
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
USD744087S1 (en) 2013-10-01 2015-11-24 Mahmut Bilgic Dry powder inhaler
US11007203B2 (en) * 2013-10-06 2021-05-18 Salim Shah Formulations comprising aldosterone receptor antagonists and treatments using same
WO2015089416A1 (en) 2013-12-12 2015-06-18 Cornell University Prolylhydroxylase/atf4 inhibitors for treating neural cell injury
FR3019045A1 (fr) * 2014-03-26 2015-10-02 Greenpharma Sas Composition dermatologique pour la repousse des poils ou des cheveux
SG11201700849XA (en) 2014-08-07 2017-03-30 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
WO2016063269A1 (en) 2014-10-20 2016-04-28 Prendergast Patrick T Use of antagonists to the nuclear steroid receptor alone or in combination as direct antiviral agents to inhibit alphavirus, togaviridae, arenaviridae, filoviridae, bunyaviridae, flaviviridae and rhabdoviridae
BR112017014953A2 (pt) 2015-01-12 2018-03-13 Nano Pharmaceutical Laboratories Llc microglóbulos de liberação controlada em camadas e métodos para produção dos mesmos
AU2016226279B2 (en) 2015-03-03 2021-11-11 Pharmacyclics Llc Pharmaceutical formulations of Bruton's tyrosine kinase inhibtor

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082751A (en) * 1976-02-13 1978-04-04 Bristol-Myers Company Therapeutic agents
IT1130924B (it) * 1980-03-06 1986-06-18 Secifarma Spa Procedimento per la preparazione di spironolattone micronizzato
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4753802A (en) 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4847093A (en) 1986-06-19 1989-07-11 Alza Corporation Dosage form with means for governing rate of gas formation
US5057317A (en) 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
GB8717168D0 (en) 1987-07-21 1987-08-26 Roussel Lab Ltd Controlled-release device
NZ238867A (en) 1990-07-12 1993-08-26 Alza Corp Dosage form for delayed release comprising pharmaceutically active substance and a drug-release hindering means and a second composition which imbibes fluid, expands, and ejects the active substance from the device
WO1992013547A1 (en) 1991-02-07 1992-08-20 Alexander Mellon Eaton Drug delivery composition and method of using the same
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
GB9311191D0 (en) 1993-05-29 1993-07-14 Danbiosyst Uk Controlled release drug formulation
AU5692398A (en) 1996-12-09 1998-07-03 Proscript, Inc. Substituted 5-amino-1,3,4-thiadiazole-2-thiones
CA2273343C (en) 1996-12-11 2006-10-10 G.D. Searle & Co. Processes for preparation of 9,11-epoxy steroids and intermediates useful therein
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
PT1175220E (pt) * 1999-12-08 2005-07-29 Pharmacia Corp Composicoes de eplerenona em nanoparticulas

Also Published As

Publication number Publication date
US20020136775A1 (en) 2002-09-26
HU224428B1 (hu) 2005-09-28
NO20012782L (no) 2001-07-03
EP1135139B1 (de) 2003-09-10
ES2207977T3 (es) 2004-06-01
KR100671275B1 (ko) 2007-01-19
HUP0104718A3 (en) 2002-10-28
PL198425B1 (pl) 2008-06-30
IL143301A0 (en) 2002-04-21
ID30115A (id) 2001-11-08
CA2326842A1 (en) 2000-06-15
DK1135139T3 (da) 2004-01-05
US6410054B1 (en) 2002-06-25
US20030215518A1 (en) 2003-11-20
HK1041641B (zh) 2006-04-28
BR9915964A (pt) 2001-08-28
IS2325B (is) 2007-12-15
AU763166B2 (en) 2003-07-17
NZ511869A (en) 2003-05-30
CN1230179C (zh) 2005-12-07
IS5953A (is) 2001-05-25
AU1936800A (en) 2000-06-26
US7157101B2 (en) 2007-01-02
ATE249223T1 (de) 2003-09-15
DE69911240T2 (de) 2004-07-15
US6863902B2 (en) 2005-03-08
TR200101643T2 (tr) 2002-04-22
AR028982A1 (es) 2003-06-04
MY125651A (en) 2006-08-30
KR20010101132A (ko) 2001-11-14
US6495165B1 (en) 2002-12-17
US6558707B1 (en) 2003-05-06
WO2000033847A1 (en) 2000-06-15
HUP0104718A2 (hu) 2003-01-01
EA200100519A1 (ru) 2002-02-28
EA003266B1 (ru) 2003-02-27
TWI234459B (en) 2005-06-21
ZA200104361B (en) 2002-05-28
US6534093B1 (en) 2003-03-18
US20040192661A1 (en) 2004-09-30
US20030072808A1 (en) 2003-04-17
US6592902B2 (en) 2003-07-15
PT1135139E (pt) 2004-02-27
NO20012782D0 (no) 2001-06-06
UA74141C2 (uk) 2005-11-15
HK1041641A1 (en) 2002-07-19
CN1329494A (zh) 2002-01-02
CZ20011942A3 (cs) 2001-12-12
JP2002531508A (ja) 2002-09-24
EP1135139A1 (de) 2001-09-26

Similar Documents

Publication Publication Date Title
ATE249223T1 (de) Zusammensetzungen, enthaltend mikronisiertes eplerenon
ATE293977T1 (de) Nanopartikelzusammensetzungen enthaltend eplerenon
ID26549A (id) Komposisi-komposisi epotilon
ATE367793T1 (de) Schweisshemmende zusammensetzungen
DE69838130D1 (de) Riechstoffzusammensetzungen
ATE285222T1 (de) Antiperspirant-zusammensetzungen
DE69903404T2 (de) Celecoxib-Zusammensetzungen
IS5046A (is) Lyfjasamsetningar
DE69933200D1 (de) Kombinierte impfstoffzusammensetzungen
DE69900634D1 (de) Shampoozusammensetzungen
ATE469550T1 (de) Antiparasitäre zusammensetzungen
HUP0102483A3 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
DE69935172D1 (de) Imidosilan Zusammensetzungen
DE60007731D1 (de) Schweisshemmende zusammensetzungen
ID27889A (id) Komposisi-komposisi kopolimer polisiklik
FR2787721B1 (fr) Compositions extinctrices
IS2200B (is) Lyfjasamsetningar
FI20012140A (fi) Uudet kvaternääriset yhdisteet, niitä sisältävät koostumukset ja niiden käyttöjä
DE69904800D1 (de) N-Acetonylbenzamide enthaltende fungizide Zusammensetzungen
ID30320A (id) Komposisi-komposisi berpigmen
DE69908923D1 (de) 1,3,4-thiadiazolylazofarbstoffe-enthaltende tintenzusammensetzungen
DE60020836D1 (de) Flammhemmende zusammensetzungen
IT1304174B1 (it) Composizioni perossidiche
SE9804309D0 (sv) Powder compositions
SE9902635D0 (sv) New compositions

Legal Events

Date Code Title Description
8364 No opposition during term of opposition